Fennec Pharmaceuticals (FENC) Receivables (2022 - 2026)
Fennec Pharmaceuticals' (FENC) quarterly Receivables came in at $23.2 million in Q4 2025, up 80.23% YoY from $12.9 million in Q4 2024, and up 20.05% on a QoQ basis from $19.3 million in Q3 2025.
Fennec Pharmaceuticals (FENC) Receivables (2022 - 2026) Analysis & Trends
Fennec Pharmaceuticals (FENC) has 4 years of Receivables data on file, last reported at $23.2 million in Q4 2025.
- Quarterly Receivables rose 80.23% year-over-year to $23.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $23.2 million (up 80.23% YoY) and the FY2025 annual result came in at $23.2 million, up 80.23% from the prior year.
- Receivables rose to $23.2 million in Q4 2025, from $19.3 million in the prior quarter.
- In the past five years, Receivables ranged from a high of $23.2 million in Q4 2025 to a low of $1.5 million in Q4 2022.
- A 4-year average of $11.0 million and a median of $12.3 million in 2024 frame the typical range for Receivables.
- Annual changes were most pronounced in 2024 — Receivables soared 510.46% — and 2025, when it surged 42.15%.
- Tracing FENC's Receivables over 4 years: stood at $1.5 million in 2022, then surged by 470.49% to $8.8 million in 2023, then jumped by 46.18% to $12.9 million in 2024, then surged by 80.23% to $23.2 million in 2025.
- The last three Receivables figures came in at $23.2 million (Q4 2025), $19.3 million (Q3 2025), and $17.5 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.93 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.06 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1.84 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 912.74 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 215.33 Mn |
| 10 | Fennec Pharmaceuticals | 410.60 Mn | 369.35 Mn | 17.15 Mn | 23.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 23.27 Mn |
| Dec 31, 2025 | 23.22 Mn |
| Sep 30, 2025 | 19.34 Mn |
| Jun 30, 2025 | 17.50 Mn |
| Mar 31, 2025 | 15.45 Mn |
| Dec 31, 2024 | 12.88 Mn |
| Sep 30, 2024 | 12.91 Mn |
| Jun 30, 2024 | 12.31 Mn |
| Mar 31, 2024 | 10.27 Mn |
| Dec 31, 2023 | 8.81 Mn |
| Sep 30, 2023 | 4.53 Mn |
| Jun 30, 2023 | 2.45 Mn |
| Mar 31, 2023 | 1.68 Mn |
| Dec 31, 2022 | 1.55 Mn |